U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H12F6N4O
Molecular Weight 450.3366
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-971086

SMILES

CC1=CC2=C(C=CC(C#N)=C2C(F)(F)F)N1CC3=NOC(=N3)C4=CC=CC(=C4)C(F)(F)F

InChI

InChIKey=ZEDODTZELVBHTG-UHFFFAOYSA-N
InChI=1S/C21H12F6N4O/c1-11-7-15-16(6-5-13(9-28)18(15)21(25,26)27)31(11)10-17-29-19(32-30-17)12-3-2-4-14(8-12)20(22,23)24/h2-8H,10H2,1H3

HIDE SMILES / InChI

Approval Year

Name Type Language
GSK-971086
Common Name English
2-METHYL-4-(TRIFLUOROMETHYL)-1-((5-(3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-3-YL)METHYL)INDOLE-5-CARBONITRILE
Systematic Name English
GSK-971086A
Code English
Code System Code Type Description
PUBCHEM
86620664
Created by admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
PRIMARY
CAS
1018971-95-3
Created by admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
PRIMARY
FDA UNII
8TFL50092H
Created by admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
GSK-971086
Created by admin on Sat Dec 16 10:26:43 GMT 2023 , Edited by admin on Sat Dec 16 10:26:43 GMT 2023
PRIMARY Official Title: A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers; Purpose: This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses.